Compare Linde PLC (LIN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Spyre Therapeutics Inc. Common Stock — how do they compare? Linde PLC trades at $496.13 (market cap $226.85B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Linde PLC is far larger — about 30.2× Spyre Therapeutics Inc. Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LIN | SYRE | |
|---|---|---|
Market Cap | $226.85B | $7.52B |
Volume | 1,386,042 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $108.92 |
52-Week Low | $389.38 | $22.18 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $6.52B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $487.35, up 0.75% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 20.43% net margins, and robust cash flow generation. Analyst consensus is overwhelmingly bullish with a $558.91 price target, representing 15% upside potential. Recent Q2 2026 results exceeded expectations with $4.50 EPS, driven by volume and pricing growth across key markets including electronics.
LIN offers quality exposure to industrial gases with AI chip contract potential, though elevated P/E of 31.75 requires sustained growth. Risks include margin pressure from higher CAPEX and sector-wide competition. The stock presents a compelling opportunity for investors seeking stable industrial exposure with growth catalysts, supported by strong institutional backing and consistent dividend payments.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
